OLMA - CIK 0001750284
Olema Pharmaceuticals, Inc. (OLMA) reported net income of -$162.45M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$162.45M | -25.5% |
| FY 2024 | -$129.47M | -34.0% |
| FY 2023 | -$96.66M | +7.8% |
| FY 2022 | -$104.79M | -47.4% |
| FY 2021 | -$71.10M | -221.4% |
| FY 2020 | -$22.12M | -412.5% |
| FY 2019 | -$4.32M | - |
Olema Pharmaceuticals, Inc. (OLMA) reported net income of -$162.45M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Olema Pharmaceuticals, Inc.'s net income declined from -$4.32M to -$162.45M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.